A Phase II Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Lenalidomide in Lumbar Radicular Pain with a Long-Term Open-Label Extension Phase.

OBJECTIVE: This phase II study assessed lenalidomide efficacy and safety. DESIGN: Three-phase core study: 14-day prerandomization, 12-week treatment, and 52-week open-label extension. SETTING: Fourteen US centers from July 2005 to July 2007. SUBJECTS: Chronic lumbar radicular pain patients without history of nerve injury or deficit. METHODS: Subjects were randomized (1:1) to double-blind treatment with lenalidomide 10 mg or placebo once daily for 12 weeks, followed by a 52-week open-label extension. A 12-week, single-center, randomized-withdrawal (1:2, lenalidomide:placebo), exploratory study with open-label extension was undertaken in 12 subjects from the core extension who were naïve to neuropathic medications and with at least a two-point decrease from baseline average daily Pain Intensity-Numerical Rating Scale score. RESULTS: Of 180 subjects enrolled, 176 had at least one postbaseline measure; 132 completed the 12-week treatment phase. In the core study, no statistically significant difference in Pain Intensity-Numerical Rating Scale mean change (-0.02, P = 0.958) was observed at week 12 between lenalidomide and placebo; proportions achieving pain reduction at week 12 and other secondary measures were comparable between lenalidomide and placebo. In the exploratory study, week 12 mean changes in Pain Intensity-Numerical Rating Scale scores were -0.05 (lenalidomide: N = 3) and 2.11 (placebo: N = 8). Mean changes in Brief Pain Inventory-short form interference scores were -3.33 and 8.38, respectively; scores at six months were maintained or decreased in 10 of 12 subjects. CONCLUSIONS: While this study does not support lenalidomide use in an unselected lumbar radicular pain population, an immunomodulating agent may relieve pain in select subjects naïve to neuropathic pain medications.ClinicalTrials.gov identifier: NCT00120120

The Lantern, 2014-2015

• The Retreat • Part of Eve\u27s Discussion • Buchanan • Hypotheticals • The Baby Hippo • Sertraline and Cheerios • Margins • Anatomy of Me • Orange • Ode to Mathematics • Garden Path • Periphery • 10n Power=Our Maybe Domains • Hillside • Baltimore//Analogues • Work is a Religion • At the Bridal Shower • November • Revisionist History • Cold Front • Lung (for D. Avitabile) • Tether • Hold Still • Reverb • An Almost English Major and His Daughter • Clocks • In the Kitchen on a Sunday Afternoon • Amy • Nine • Customary Thoughts • Showers • Te Encuentro • I Find You • Literary Analysis • The Diamond on My Face • Catherine • Hunsberger Woods, 11:42 on a School Night • Cabbage • After Class • For Chell • To Whom It May Concern • Contra • Shards • Smoke and Roses • Polaroid • Spring\u27s Debut • The Deadline • A Previous Life • Wet Canvas • Obsessions and Compulsions • For Xandra • The Seagulls of 17th Street • No Man\u27s Land • Summer Flowers • Float • Dana Reads • A Barcelona Moment • Business Meeting • Posted • Champagnehttps://digitalcommons.ursinus.edu/lantern/1181/thumbnail.jp

β-globin gene transfer to human bone marrow for sickle cell disease

Autologous hematopoietic stem cell gene therapy is an approach to treating sickle cell disease (SCD) patients that may result in lower morbidity than allogeneic transplantation. We examined the potential of a lentiviral vector (LV) (CCL-βAS3-FB) encoding a human hemoglobin (HBB) gene engineered to impede sickle hemoglobin polymerization (HBBAS3) to transduce human BM CD34(+) cells from SCD donors and prevent sickling of red blood cells produced by in vitro differentiation. The CCL-βAS3-FB LV transduced BM CD34(+) cells from either healthy or SCD donors at similar levels, based on quantitative PCR and colony-forming unit progenitor analysis. Consistent expression of HBBAS3 mRNA and HbAS3 protein compromised a fourth of the total β-globin–like transcripts and hemoglobin (Hb) tetramers. Upon deoxygenation, a lower percentage of HBBAS3-transduced red blood cells exhibited sickling compared with mock-transduced cells from sickle donors. Transduced BM CD34(+) cells were transplanted into immunodeficient mice, and the human cells recovered after 2–3 months were cultured for erythroid differentiation, which showed levels of HBBAS3 mRNA similar to those seen in the CD34(+) cells that were directly differentiated in vitro. These results demonstrate that the CCL-βAS3-FB LV is capable of efficient transfer and consistent expression of an effective anti-sickling β-globin gene in human SCD BM CD34(+) progenitor cells, improving physiologic parameters of the resulting red blood cells